Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance study of duvakitug in moderately to severely active ulcerative colitis
CTR20261063Phase 3Active
- Sponsor
- Sanofi
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of duvakitug in autoimmune colitis, sponsored by Sanofi. Started Sep 2026; status: active.
02
Drugs
duvakitug
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20261063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261063.